Stockpolly
Search
GALT · NASDAQ · Biotechnology

Galectin Therapeutics (GALT)

Develops belapectin, a galectin-3 inhibitor, for MASH cirrhosis with portal hypertension.

$4.35
Pre-market−0.14 (−3.12%)
At close$4.49(+7.67%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
9101011912854344
Research & development88810811633222
112111112122
General & administrative112111112122
Operating income−9−10−10−11−9−12−8−5−4−3−4−4
−10−2−1−20−2−3−4−2−1−5
Interest income000000000000
Interest expense111112222222
Other non-operating income00101−20120−1−3
Income before tax−10−10−11−12−11−12−10−8−8−6−5−9
Net income from continuing operations−10−10−11−12−11−12−10−8−8−6−5−9
Net income−10−10−11−12−11−12−10−8−8−6−5−9
EPS, basic−$0.24−$0.16−$0.19−$0.20−$0.18−$0.19−$0.15−$0.12−$0.13−$0.08−$0.08−$0.14
EPS, diluted−$0.24−$0.16−$0.19−$0.20−$0.18−$0.19−$0.15−$0.12−$0.13−$0.08−$0.08−$0.14
Weighted average shares, basic606062626263636364646666
Weighted average shares, diluted606062626263636364646666
EBITDA−10−9−10−11−10−10−8−6−6−4−3−1
Depreciation & amortization000000000000
EBIT−10−9−10−11−10−10−8−6−6−4−3−1